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UBAT-UBATAN GENERIK: PENGETAHUAN, PERSEPSI DAN PRAKTIS 
AHLI FARMASI KOMUNITI, AHLI PERUBATAN DAN PENGGUNA UBAT-
UBATAN DI RIYADH, ARAB SAUDI 
 
 
ABSTRAK 
 
 
Ubat-ubatan generik secara lazimnya adalah sama seperti ubat-ubatan berjenama asli. Ia 
membekalkan hasil teraupetik yang sama, pada kos yang lebih rendah. Disebabkan itu, 
ubat-ubatan ini dipromosikan di pelbagai negara sebagai salah satu langkah untuk 
mengatasi kos perbelanjaan farmaseutikal yang kian meningkat. Di Arab Saudi, 
penggunaan ubat-ubatan generik pada masa ini adalah rendah. Oleh sebab itu, peranan 
serta pengaruh ahli farmasi komuniti dan pengguna perubatan dalam mengalakkan 
penggunaan ubat-ubatan generik adalah sangat penting. Oleh yang demikian, projek ini 
berfokus kepada kajian mengenai pengetahuan,persepsi dan praktis penggunaan ubat-
ubatan generik. Dalam bahagian pertama tesis ini, tiga kajian kualitatif telah dijalankan 
dengan menggunakan sesi temubual separa berstruktur secara bersemuka bersama 
individu yang terlibat. Kajian kualitatif pertama dijalankan bersama 20 ahli farmasi 
komuniti. Kajian tersebut mendapati penukargantian generik proaktif bukanlah satu 
praktis yang menjadi kebiasaan di kalangan ahli farmasi komuniti. Tambahan lagi, 
terdapat faktor berbeza yang berkait dengan ahli farmasi komuniti, ahli perubatan dan 
pesakit yang menghalang mereka daripada praktis penukargantian generik. Kajian 
kedua dilakukan bersama 18 ahli perubatan. Kajian tersebut mendapati perskripsi 
khusus kepada produk dijadikan sebagai model praktis berbanding dengan perskripsi 
generik (INN) yang pada masa ini bukanlah satu praktis kebiasaan. Tambahan lagi, 
pelbagai faktor mempengaruhi ahli perubatan dalam memilih jenama ubat-ubatan 
tersebut, termasuklah faktor yang berkaitan dengan ahli perubatan tersebut, faktor yang 
xxxii 
 
berkaitan dengan pengeluar/pengilang dan produk ubat-ubatan itu. Faktor yang 
berkaitan dengan pesakit, dan faktor yang berkaitan dengan pemasaran farmaseutikal. 
Kajian ketiga dijalankan bersama 15 pengguna perubatan. Kajian tersebut mendapati 
pengguna perubatan secara amnya lebih menggemari penggunaan ubat-ubatan 
berjenama asli berbanding dengan ubat-ubatan generik. Tambahan pula, terdapat 
banyak pengguna yang mempunyai persepsi negatif dan tanggapan salah mengenai 
ubat-ubatan generik. Perkara paling penting dalam hal ini, cadangan (dalam memberi 
perskripsi dan mendispens) oleh ahli perubatan dan ahli farmasi adalah faktor utama 
yang mempengaruhi penggunaan dan kadar penerimaan ubat-ubatan generik oleh 
pesakit. Dalam bahagian kedua tesis ini, dua kajian keratan rentas kuantitatif yang 
menggunakan borang soal selidik telah dijalankan. Salah satu kajian dijalankan bersama 
251 ahli perubatan yang menjalankan praktis di poliklinik (kadar respons = 59.3%). 
Dalam kajian ini, 128 (51%) menyatakan yang mereka telah memberi perskripsi kedua-
dua ubat-ubatan generik dan ubat-ubatan berjenama asli lebih kurang pada  nisbah yang 
sama, 76 (30.3%) menyatakan mereka lebih banyak memberi perskripsi ubat-ubatan 
berjenama asli dan 46 (18.3%) menyatakan mereka lebih banyak memberi perskripsi 
ubat-ubatan generik.Satu kajian lain turut dijalankan bersama 381 ahli farmasi komuniti 
(kadar respons = 90.1%). Dalam kajian ini, hampir kesemua responden (379; 99.5%) 
menyatakan dalam kebanyakan situasi, mereka mengagih dan mendispens ubat-ubatan 
mengikut jenama dalam perskripsi yang diberikan tanpa menawarkan penukargantian 
generik. Mengenai praktis utama dalam mendispens ubat-ubatan OTC, 153 (40.2%) 
menyatakan mereka menawarkan ubat-ubatan generik kepada pengguna, 124 (32.5%) 
responden menawarkan ubat-ubatan berjenama, 101 (26.5%) responden menawarkan 
xxxiii 
 
kedua-dua jenama ini, kadangkala mereka menawarkan ubat-ubatan generik atau 
berjenama, dan hanya tiga responden (0.8%) menyatakan mereka menawarkan kedua-
dua ubat-ubatan generik dan berjenama ini kepada pengguna untuk mereka membuat 
pilihan sendiri. Dapatan kajian utama dalam kajian kuantitatif ini menunjukkan bahawa 
terdapat sebilangan besar ahli perubatan dan ahli farmasi komuniti yang mempunyai 
tanggapan salah dan persepsi negatif terhadap ubat-ubatan generik. Kesimpulannya, 
salah satu cara dalam meningkatkan penggunaan ubat-ubatan generik adalah dengan 
mempromosikannya melalui pendekatan holistik dengan mengambil kira perspektif 
pihak berkepentingan, termasuklah ahli perubatan, ahli farmasi komuniti dan pengguna 
perubatan.  
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GENERIC MEDICINES: KNOWLEDGE, PERCEPTIONS AND PRACTICE OF 
COMMUNITY PHARMACISTS, PHYSICIANS AND MEDICINE 
CONSUMERS IN RIYADH, SAUDI ARABIA 
 
 
ABSTRACT  
 
Generic medicines are essentially the same as their counterpart brand medicines. They 
provide the same therapeutic outcomes, but at a much cheaper price. Therefore, they are 
promoted in many countries to confront the problem of escalating pharmaceutical 
expenditures. In Saudi Arabia, the use of generic medicines is currently low. Therefore, 
to promote generic medicines, the roles of physicians, community pharmacists and 
medicine consumers are essential. Hence, this research project aimed to study their 
knowledge, perceptions and practice regarding the use of generic medicines. In the first 
part of the thesis, three qualitative studies were conducted, using face-to-face individual 
semi-structured interviews. The first qualitative study was conducted with 20 
community pharmacists. The study findings showed that proactive generic substitution 
is currently not a common practice in community pharmacies. Moreover, different 
factors related to community pharmacists, physicians and patients hindered the generic 
substitution practice. The second qualitative study was conducted with 18 physicians. 
The study findings showed that generic (international nonproprietary name) prescribing 
is currently not a common practice but rather product-specific prescribing is the practice 
model. Moreover, different factors influenced the physicians’ choice of the brands of 
medicines, including factors related to the physician, factors related to the drug product 
and its manufacturer/drug company, factors related to the patient, and factors related to 
pharmaceutical marketing. The third qualitative study was conducted with 15 medicine 
consumers. The study findings showed that medicine consumers generally preferred the 
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use of brand medicines over generic medicines. Moreover, many consumers have 
negative perceptions and misconceptions about generic medicine. More importantly, 
recommendations (i.e. prescribing and dispensing) by physicians and pharmacists were 
the main factors influencing the use and acceptance of generic medicines by patients. In 
the second part of the thesis, two quantitative cross-sectional questionnaire-based 
studies were conducted. One study was conducted with 251 physicians practising in 
polyclinics (response rate = 59.3%). In this study, 128 (51%) stated that they prescribe 
both generic medicines and original brand medicines at approximately the same ratio, 
76 (30.3%) stated that they prescribe more original brand medicines and 46 (18.3%) 
stated that they prescribe more generic medicines. Similarly, another study was 
conducted with 381 community pharmacists (response rate = 90.1%). In this study, 
almost all participants (379; 99.5%) stated that they dispense brand medicine in the 
prescription as written by prescribers without offering generic substitution in most 
situations. Regarding the main dispensing practice for OTC medicines, 153 (40.2%) 
stated that they offer generic medicines to consumers, 124 (32.5%) participants offer 
brand medicines, 101 (26.5%) participants offer both – sometimes they offer generic 
medicines and sometimes brand medicines – and only three participants (0.8%) stated 
that they offer both original brand and generic medicines and left the choice to the 
consumer. The quantitative studies showed that a considerable proportion of physicians 
and community pharmacists have misconceptions and negative perceptions of generic 
medicines. In conclusion, to increase utilization of generic medicines, it needs to be 
promoted in a holistic approach by considering the perspectives of all stakeholders, 
including physicians, community pharmacists and medicine consumers. 
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CHAPTER ONE: GENERAL INTRODUCTION  
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1.1 Background 
Generic medicine can be defined in different ways (Birkett, 2003; Davit et al., 2013; 
Dunne et al., 2013). However, the term is commonly understood as defined by the 
World Health Organization (WHO) as ‘a pharmaceutical product, usually intended to be 
interchangeable with an innovator product that is manufactured without a licence from 
the innovator company and marketed after the expiry date of the patent or other 
exclusive rights’ (WHO, 2012, para. 1). Generic medicines are required to have the 
same active substance, strength, route of administration, identity, quality, purity, 
efficacy and the same intended use as their counterpart brand medicines (US Food and 
Drug Administration (FDA), 2012a; European Generic Medicines Association (EGA), 
2013a; Saudi Food and Drug Authority (SFDA), 2013a) but they can be different in 
some aspects, such as the inactive ingredient, colour,  shape and product packaging 
(EGA, 2007; US FDA, 2012a). Before registration, similar to all medicines including 
original brand medicines, generic medicines must pass through a rigorous registration 
process and stringent requirements to ensure their quality, safety and efficacy, and that 
they meet all the required standards (SFDA, 2009; US FDA, 2012a; EGA, 2013a; 
SFDA, 2013a)  Furthermore, the concept of bioequivalence is an essential requirement 
for approval of generic medicines in many countries (Galgatte et al., 2013), including 
Saudi Arabia  (Executive Board of the Health Ministers’ Council for GCC States, 
2013a). Bioequivalence is performed to demonstrate the clinical equivalence of the 
generic medicine with its counterpart original brand and to allow a bridging with the 
clinical studies performed on the original medicine. Hence repeating preclinical and 
clinical testing done on the original brand is not required (European Medicines Agency 
(EMA), 2010; Dunne et al., 2013).  
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Generic medicines are much cheaper than their equivalent brand medicine (Matin, 
1999; Simoens & Coster, 2006; Shafie & Hassali, 2008; EGA, 2013b) and are available 
as a standard therapy for many acute and chronic diseases (Sheppard 2011; EGA, 
2013b). Thus, use of generic medicines is essential to the affordability of and access to 
medicines (Cameron et al., 2009; Hassali et al., 2014). Moreover, generic medicines 
play a major role in lowering the prices of off-patent innovator medicines and other 
generic equivalents (Pharmaceutical Benefits Board (LFN), 2007; Aalto-Setälä, 2008; 
US FDA, 2010; Hassali et al., 2014). Thus, by using generic medicines, the health-care 
system can save a huge amount of money that can be utilized to pay for the more 
expensive patented and new innovative products that are needed to treat some diseases 
where generic medicines are not available (EGA, 2007). Hence, the wide use of generic 
medicines is instrumental to the creation and maintenance of sustainable health-care 
systems (Simoens, 2010). Thus, generic medicines are considered an essential part of 
the health-care system (Al-Tamimi et al., 2013).  
 
Health-care expenditure, including pharmaceutical expenditure, is steadily increasing in 
many countries around the globe. In fact, pharmaceutical expenditure is one of the rapid 
growing components of health-care expenditures (Henriksson et al., 1999; Schneeweiss 
et al., 2002; Ess et al., 2003; Zuvekas & Cohen, 2007; Saudi Ministry of Health 
(SMOH), 2008; Wettermark et al., 2008; Coma et al., 2009; Godman et al., 2009; 
Godman et al., 2010a; Godman et al., 2010b;  Sermet et al., 2010; Leng et al., 2011; 
Hoffman et al., 2012; Hoffman et al., 2013). Therefore, in recent years, to confront the 
escalation of health-care expenditure in general, and pharmaceutical expenditure in 
particular, many governments and third-party payers have encouraged the use of generic 
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medicines as an integral part of the health-care system by instigating and implementing 
various policies, initiatives and strategies (Simoens & DeCoster, 2006; Sermet et al., 
2010; Godman et al., 2010a; Godman et al., 2012a; Godman et al., 2012b; Ministry of 
Health, Labour and Welfare of Japan (MHLW), 2012).  
 
Amidst them all, the role of health-care professionals (physicians and pharmacists) and 
medicine consumers/patients is an important issue and an essential factor for the wide 
use of generic medicines in the health-care system. In fact, correct understanding, 
knowledge and positive perceptions among health-care professionals and patients are 
prerequisite to the use of generic medicines (Dylst et al., 2013; Hassali et al. 2014). 
Therefore, the aim of this thesis is to study the perspectives of health-care professionals 
(physicians and community pharmacists) and medicine consumers/patients of generic 
medicines and current issues surrounding their use in the Saudi health-care system.     
 
1.2 Rationale and significance of the study 
In Saudi Arabia, the total health expenditure is steadily increasing; it has increased 
tremendously by approximately 165% over one decade (2000−2011). It increased from 
approximately SAR 30.100 billion in 2000 to SAR 79.795 billion in 2011 (1 Saudi 
Riyal (SAR) = 3.75 US dollar) (WHO, 2011). Similarly, pharmaceutical expenditure 
has greatly increased in recent years. Within a span of only four years, it increased by 
approximately 69% from SAR 12.06 billion in 2009 to reach SAR 20.37 billion in 
2012. Thus, pharmaceutical expenditure represented approximately 23.15% of the total 
health expenditure in 2012 (Business Monitor International (BMI), 2013a).  In fact, the 
pharmaceutical expenditure is one the most  fast-growing components of health-care 
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expenditure in Saudi Arabia (SMOH, 2008).  Meanwhile, generic medicines represented 
only 8.12% of the total medicine market and only 9.1% of the prescription medicines 
market in 2012. Moreover, it is forecasted to reach only approximately 11.5% in 2020 
(BMI, 2013a). In fact, the Saudi drug market is heavily dominated by original and 
patented medicine brands. These represented approximately 80.8% of the total medicine 
market and 90.9% of the prescription medicines market in 2012 (BMI, 2013a). 
Therefore, to confront the escalating health-care cost in general and pharmaceutical 
expenditure in particular, it is essential to promote the use of generic medicines in the 
Saudi health-care system. As shown in Figure 1.1, for the promotion of generic 
medicines, policies, strategies and initiatives are broadly classified into two categories 
(Godman et al., 2010b). One category is the supply-side measures (i.e. those policies 
related to the prices and pricing system of generic medicines e.g. reference pricing 
system) and the other category is called the utilization or demand-side measures. The 
latter targets health-care professionals and patients/consumers and aims to ensure that 
they are supporting the use of generic medicines, to address any barriers or obstacles 
that may hinder the quality use of generic medicines and to introduce policies that 
facilitate the wide use of generic medicines by targeting key players, namely physicians, 
pharmacists and medicine consumers (i.e. it addresses knowledge, perceptions, practice, 
barriers to or facilitators of prescribing, dispensing or using generic medicines among 
physicians, pharmacists and patients, respectively) (Godman et al., 2010b). In fact, the 
essential difference between mature generic markets and developing generic markets is 
the presence/absence of demand-side policies (Simoens, 2013).   
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Figure 1.1 Policies and factors influencing access and utilization of generic 
medicines in the health system (adapted and modified from: Godman et al., 2010b; 
Simoens, 2013) 
 
 
 
 
Currently, in Saudi Arabia, based on an extensive literature search in several electronic 
research databases and search engines, there is a paucity of data regarding the 
perspectives of physicians, community pharmacists and patients of generic medicines. 
Moreover, the extrapolation of findings of other studies conducted in other countries is 
not appropriate due to the large differences between health-care systems (Hassali et al., 
2005a; Hassali et al., 2014). In fact, although it could be useful to learn from the 
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possible to extrapolate the findings from these different health-care systems to the local 
situation in Saudi Arabia due to the substantial differences in the health policies, health 
systems, medicine regulations and the views and practices of health-care professionals 
from one country to another (Hassali et al., 2005a; Hassali et al., 2014). Therefore, it is 
highly important to study the perspectives of physicians, community pharmacists and 
patients on the use of generic medicines in Saudi Arabia.   
 
According to the WHO (2001, p. 4), a national medicine policy is ‘a commitment to a 
goal and a guide for action’ with the objective of promoting equity and sustainability of 
both public and private pharmaceutical sectors. In addition, it should ensure not only the 
availability and accessibility to high-quality, safe and effective medicines, but also 
promote the cost-effective use of medicines to health-care professionals and consumers 
(WHO, 2001). Therefore, the promotion of generic medicines is recommended to be 
included as part of a national medicine policy (Cameron et al., 2012) as it helps to 
achieve a comprehensive and sustainable health-care system in developed countries 
(Godman et al., 2010a) and improve the affordability, and thus accessibility of 
medicines in developing countries (Cameron et al., 2009). In fact, generic medicine 
utilization has led to substantial cost savings for health-care systems (Andersson et al., 
2007; Coombes, 2009; The Social Insurance Institution of Finland (KELA) 2009; 
Sheppard, 2011; Generic Pharmaceutical Association, 2012; EGA, 2013c). For 
example, in the US, generic medicines saved the health-care system approximately one 
trillion dollars over ten years from 2002 to 2011 (Generic Pharmaceutical Association, 
2012). Therefore, the use of generic medicines needs to be promoted in Saudi Arabia to 
confront the escalating pharmaceutical expenditure. In view of the current low 
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utilization of generic medicines in the country, there is large scope to further increase 
the use of generic medicines. Thus, this research project would provide health 
authorities and other involved parties and stakeholders with valuable data related to the 
perspectives of physicians, community pharmacists and patients, and related to current 
issues surrounding the use of generic medicines. This research project would provide 
useful data that could be used to inform the design or implementation of strategies, 
initiatives, or programmes to promote generic medicines, such as educational 
interventions or educational campaigns targeting physicians, pharmacists and 
patients/medicine consumers.    
    
1.3 Ethical approval of the research project 
The research project was granted ethical approval by the Human Research Ethics 
Committee at the College of Pharmacy, Qassim University (approval number: 501-K-
11) (Appendix A). Also, a letter was given by the research centre, the College of 
Pharmacy, Qassim University to show that the researcher is a PhD student and 
conducting a research project to study generic medicines in Saudi Arabia (Appendix B).  
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2.1 Health-care system in Saudi Arabia 
2.1.1 Saudi health-care system: a brief overview   
The Kingdom of Saudi Arabia is located in the south-west corner of Asia and covers an 
area of approximately 2 million km2; the total population reached approximately 29.2 
million in 2010 (Central Department of Statistics and Information (CDSI), 2012). Saudi 
Arabia is organized administratively into 13 administrative regions, namely Riyadh, 
Makkah, Madinah, Qassim, Eastern Province, Asir, Tabuk, Hail, Northern Border 
Province, Jazan, Najran, Baha and Al-Jouf region (Ministry of Foreign Affairs, 2006). 
Riyadh is the capital of Saudi Arabia and located in the heart of the country. In 2013, its 
population was estimated to be 5.7 million. It is estimated that 61% of population in 
Riyadh are Saudi while the rest (39%) are residents from different parts of the world 
such as, India, China, Bangladesh, Pakistan, Indonesia, Philippines, Yemen, Egypt, 
Sudan, Lebanon, Syria, Europe, US, Canada, South Africa and Russia. Thus, Riyadh is 
considered to be one of the most cosmopolitan cities in the Arab world (High 
Commission of Development of Arriyadh, 2013). 
 
The country has witnessed a huge improvement in socio-economic development during 
the past three decades. Tremendous efforts have been made to advance all sectors, 
including health, education, housing and the environment (WHO, 2007). Currently, the 
country has a good infrastructure, including an extensive network of modern roads, 
highways, airports, seaports, power, desalination plants and huge industrial complexes 
(WHO, 2007). This, in turn, has transformed the country into one of the most urbanized 
countries in the Middle East (Khaliq, 2012). 
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Similarly, the Saudi health-care system has gone through huge improvements in the last 
50 years on all levels and aspects of the health-care services in terms of quality and 
quantity (WHO, 2007; Almalki et al., 2011; Khaliq, 2012). Thus, a large network of 
modern health-care facilities, including hundreds of hospitals and thousands of primary 
care centres, are currently established in the country to provide health-care to all 
citizens and residents in the country (Almalki et al., 2011; Khaliq, 2012). In terms of 
quality of care, for example, the King Faisal Specialist Hospital & Research Centre 
(KFSH & RC) was ranked in 2013 by the Spanish National Research Council (CSIC) 
(2013) as the top hospital in the Middle East. However, the health-care system is 
currently facing many real challenges. In addition to the major challenge of escalating 
costs in providing health-care services,  there are many other factors that challenge the 
sustainability and efficiency of the system. These factors include: a shortage of local 
health-care professionals, as the majority of health-care professionals are expatriates; a 
rapid population growth; the ageing of the population; the high burden of chronic 
diseases (e.g. asthma 13%, hypertension 11%, diabetes 28%); a growing demand for 
health-care services; a poor referral system between primary centres and hospitals; long 
waiting times; the unavailability of some medicines at some periods, underutilization of 
e-health and information systems; the maldistribution of health-care services across 
geographical areas (SMOH, 2009a; Almalki et al., 2011). In the public sector, for 
example, the waiting time for non- emergency surgery might be several months to a 
year (Walston et al., 2008). Moreover, the general perception of the quality of care in 
Ministry of Health (MOH) facilities is much lower than of that in the private sector and 
other government sectors (Walston et al., 2008). Therefore, currently, sustainability and 
maintaining the efficiency of the health-care system is a major challenge (Khaliq, 
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2012). However, to address these challenges and improve the current health-care 
system, the new Saudi health strategy was introduced in 2009 to be implemented by the 
MOH in cooperation with other organizations and agencies. In this strategy, many 
issues were addressed, such as health promotion and prevention of diseases, including 
non-communicable diseases (NCDs), which are a high burden and require costly 
treatment and high utilization of the system. Thus, the expansion of primary health-care 
centres was recommended. Due to the tremendous increase in health-care expenditure, 
alternative means of funding health-care services were recommended. Thus, the cost-
effective use of medicines was encouraged to lower the escalating trend in health 
expenditure in general and pharmaceutical expenditure in particular. Moreover, the 
involvement of the private sector in the provision of health services needed to be 
increased to cover at least 50% of the total health expenditure. Also, for government 
hospitals, in addition to annual allocations from government, other modes of financing 
(e.g. the privatization of some health-care services) needed to be found (SMOH, 2009a).   
  
2.1.2. Health system organization and provision of health-care 
Health-care in Saudi Arabia is provided by a three-level system (primary, secondary and 
tertiary health-care). The concept of primary health-care (PHC) started in the early 
1980s via the establishment of PHC centres; secondary and tertiary health-care are 
provided via general and specialist hospitals. The integrated health-care services 
system, via referral with the feedback system, is the adopted approach in the provision 
of health-care. In this approach, patients who need secondary or more specialized care 
are referred to the appropriate health-care facility (Regional Health Systems 
Observatory − The Eastern Mediterranean Regional Office (EMRO), 2006; SMOH, 
2008).  
13 
 
Health-care is provided via a dual system (i.e. public and private sector). The public 
sector is currently the main provider of health-care and is funded mainly by the 
government budget. The Ministry of Health (MOH) and other government sectors are 
provided with financial appropriations on a yearly basis from the general government 
budget. Health-care services provided by the private sector are financed by cooperative 
health insurance schemes and out-of-pocket payments (Regional Health Systems 
Observatory − EMRO, 2006; SMOH, 2008). In the public sector, the Ministry of Health 
(MOH), established in 1951, is the major health-care provider as it provides 
approximately 60% of all health services (Regional Health Systems Observatory − 
EMRO, 2006; SMOH, 2008). In 2011, the MOH operated 251 hospitals and 2109 PHC 
centres.  In terms of manpower, there were 33,999 physicians (23% were Saudi), 3020 
dentists (43.1% were Saudi), 77,946 nurses (51.9% were Saudi nurses), 1897 
pharmacists (82.4% were Saudi), and 43,422 allied health personnel (87.25% were 
Saudi) (SMOH, 2011).  
 
Other government agencies also participate in the provision of health-care. However, 
unlike the MOH, health-care is provided mainly to these organizations or ministries’ 
employees and their families/dependents. These government sectors include the health-
care facilities of the Ministry of Defence and Aviation (MODA) , the Ministry of 
Interior (MOI), the Saudi Arabian National Guard (SANG), ARAMCO health services, 
health services in the Royal Commission for Jubail & Yanbua, Ministry of Education 
health units and  university teaching hospitals (SMOH, 2008; Almalki et al., 2011).  
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The private sector has grown over the years and is now considered an important 
component of the Saudi health-care system (Walston et al., 2008; Khaliq, 2012). In 
2011, there were 130 private hospitals and 2185 private polyclinics (SMOH, 2011). In 
terms of manpower in the private sector, there were 22,479 physicians, 5919 dentists, 
28,373 nurses and 10,174 allied health-care professionals. It should be noted that most 
private sector premises are located mainly in urban cities, particularly in two regions: 
Riyadh and Jeddah. In fact, 23.8% of private hospitals (n=31) are located in Riyadh and 
22.3% are located in Jeddah. Similarly, for private polyclinics, 33.5% (n=732) and 
20.8% (n=454) are located in Riyadh and Jeddah, respectively. Thus, almost half of the 
health-care sector is available in just two regions of the total 13 regions of Saudi Arabia 
(SMOH, 2011). However, the growth of this sector is rapid and the government is 
encouraging its expansion to cover all regions (SMOH, 2009).  
 
 
The community pharmacy sector represents a major component of the primary health-
care system in Saudi Arabia in general and the private sector in particular. In 2011, the 
total number of community pharmacies was 6373, which were run by 11,583 
pharmacists. In Riyadh, for example, there were 1804 community pharmacies according 
to 2011 statistics (SMOH, 2011).  
 
2.1.3 Health-care expenditure and financing 
Total health expenditure is steadily increasing; it has increased tremendously from 
approximately SAR 30.100 billion in 2000 to SAR 79.795 billion in 2011 (1 Saudi 
Riyal (SAR) = 3.75 US Dollar). General government health expenditure represented 
approximately 68.9% of the total health expenditure (SAR 55.003 billion) in 2011 
(WHO, 2011). Moreover, financial appropriations from government budget to the MOH 
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increased from approximately SAR 22.808 billion in 2007 to reach SAR 39.860 billion 
in 2011 (SMOH, 2011). Regarding health funding, in the public sector, health-care is 
mainly funded by the government budget. The Ministry of Health (MOH) and other 
government sectors are provided with financial appropriations yearly from the general 
government budget.  
 
The total private health expenditure increased tremendously from SAR 8.534 billion in 
2000 to reach SAR 24.792 billion. Hence, it represented 31.1% of total health 
expenditure in 2011.  The health-care and expenses in the private sector are financed by 
out-of-pocket payments and private health insurance (e.g. cooperative health insurance). 
In fact, currently, the expenses of health in the private sector are mainly financed by 
out-of-pocket payments, as these represented 58.1% (SAR 14.394 billion) in 2011 
(WHO, 2011). Figure 2.1 shows the trend of total health expenditure in Saudi Arabia 
from 2000−2011.  
 
 
 
 
Figure 2.1 The trend of total health expenditure in Saudi Arabia from 2000−2011 
(data source: WHO, 2011)   
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2.1.4 Saudi pharmaceutical market  
Similar to the total health expenditure, pharmaceutical expenditure increased 
tremendously from SAR 12.06 billion in 2009 to reach SAR 20.37 billion in 2012. 
Thus, pharmaceutical expenditure represented approximately 23.15% of the total health 
expenditure in 2012 (BMI, 2013a). The trend of pharmaceutical expenditure in Saudi 
Arabia for the period of 2009−2012 is presented in Figure 2.2.  
 
 
Figure 2.2 The trend of pharmaceutical expenditure in Saudi Arabia for the period 
2009−2012 (data source: BMI, 2013a) 
 
Moreover, as shown in Figure 2.3, the Saudi pharmaceutical market represented more 
than 50% of the total pharmaceutical sales of the Gulf Cooperative Council (GCC) 
countries (the GCC region includes Saudi Arabia, United Arab Emirates (UAE), Oman, 
Kuwait, Qatar and Bahrain). Also, the Saudi pharmaceutical market is currently the 
largest market in the Middle East and Africa (MEA) region (BMI, 2013a; BMI, 2013b; 
BMI, 2013c; BMI, 2013d; BMI, 2013e; BMI, 2013f). 
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Figure 2.3 Pharmaceutical expenditure in GCC countries in 2012 (data source: 
BMI, 2013a; BMI, 2013b; BMI, 2013c; BMI, 2013d; BMI, 2013e; BMI, 2013f) 
 
Regarding original brand medicines and generic medicines, the Saudi market is heavily 
dominated by original and patented medicine brands. These represented approximately 
80.8% of the total medicine market and 90.9% of the prescription medicines market in 
2012. On the other hand, generic medicines represented only 8.12% of the total 
medicine market and only 9.1% of the prescription medicines market in 2012. 
Moreover, this is forecasted to reach approximately 11.5% in 2020 (BMI, 2013a). The 
over-the-counter market represented approximately 11.06% of the market in 2012 
(BMI, 2013a). 
 
In Saudi Arabia, local pharmaceutical companies produce only approximately 16% of 
the domestic pharmaceuticals. Moreover, a large number of these medicines produced 
by local companies are not generic products but patented medicines produced by 
               KSA             UAE           Kuwait          Qatar          Oman         Bahrain  
Billion 
(USD) 
18 
 
licensing from multinational companies (BMI, 2013a). The presence of multinational 
drug companies is extensive in the Saudi market. The USA and European countries are 
the major suppliers of medicines to the market. Also, several drug companies from the 
Middle East such as Egypt, Jordon, UAE and Oman have a presence in the Saudi drug 
market (BMI, 2013a).   
  
2.1.5 Regulation and registration of generic medicines in Saudi Arabia 
The Saudi Food and Drug Authority (SFDA), established in 2003, is the national 
regulatory body responsible for the regulation, registration and approval of medicines in 
Saudi Arabia. Hence, one of its main objectives is to ensure and observe the 
effectiveness, safety and quality of medicines (SFDA, 2013b). In addition, it is 
responsible for developing and implementing policies and procedures related to 
medicines. Moreover, as well as the regulatory role, it is tasked with consumer 
awareness on all matters related to medicines (SFDA, 2013b). Historically, the Ministry 
of Health (MOH) was the regulatory body responsible for the regulation, approval and 
registration of medicines in the country. In 2003, the SFDA was established as an 
independent body that directly reports to the President of the Council of Ministers. It 
stated its regulatory role in two phases. In the first phase, which lasted five years, the 
SFDA developed and reviewed all policies, guidelines, regulations and standard 
specifications related to food, medicines and medical devices. In the second phase, in 
2008, the SFDA started its regulatory and supervisory tasks and started receiving 
submissions for the approval and registration of medicines (SFDA, 2013b). 
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The SFDA applies strict requirements and a rigorous registration system to ensure the 
efficacy, safety and quality of generic medicines (SFDA, 2009; SFDA, 2013a). In fact, 
the registration system in Saudi Arabia applies the most stringent policies in the Middle 
East (Tantash, 2012). In Saudi Arabia, manufacturers and drug companies must seek 
approval from the SFDA before marketing any medicine. Moreover, manufacturers and 
drug companies must first register with the SFDA to be able to register their products in 
the country (SFDA, 2011a).  Regarding generic medicines’ approval and registration, as 
shown in Figure 2.4, according to the Regulatory Framework for Drug Approvals 
Version 4 (SFDA, 2009), the generic medicines will be assessed over a six-process 
procedure before being granted market authorization (MA) as follows: 
Figure 2.4 The generic medicines approval process for granting market authorization 
(data source: SFDA, 2009)  
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• Validation process: in this process, the SFDA will validate and evaluate the drug file 
in terms of the completeness and accuracy of all the information according to the 
SFDA generic medicine market authorization requirements and procedure. At this 
stage, the manufacturer must provide samples of the product for testing in a further 
step. 
• Assessment process: in this process, the product file will be assessed by two groups, 
namely the quality and efficacy teams in the SFDA.  The product file can proceed to 
the next step only after recommendation for approval and successfully passing the 
quality and efficacy assessment, otherwise it will be rejected.    
• Pricing process: the price of the product will be determined by the pricing unit 
according to the SFDA pricing rules. 
• Testing process: the drug samples received from the drug company will be sent to 
the laboratory for testing. 
• Inspection process: in this process, the SFDA will check the product manufacturing 
line to ensure compliance with current good manufacturing practice (GMP). It must 
hold a valid certificate from the Saudi MOH or SFDA, otherwise, an inspection 
team will be sent to check the line before granting the approval. 
• Product licensing: this is the final stage in which the product will be granted 
marketing authorization (MA) based on reviewing all the reports (quality and 
efficacy assessment reports, pricing report, testing report, GMP inspection report 
and company registration) by the SFDA registration committee.  
• Appeal process: the company has the right to appeal within 30 days of the final 
decision by the SFDA.  
 
21 
 
After approval and before marketing, the first batch must be tested by the SFDA before 
distribution to make sure it meets the required specifications. After testing, the company 
will be notified with the result as they can distribute their product only after notification. 
However, if the company is not notified within 35 days, it may distribute the product 
under their own liability (SFDA, 2009). In addition, the National Pharmacovigilance  
Centre (NPC), under the umbrella of the SFDA, is responsible for post-marketing drug 
surveillance (SFDA, 2009).   
 
2.1.6 Pricing policy of generic medicines 
The medicine prices in Saudi Arabia are strictly controlled. Moreover, article no. 14 of 
the Pharmacy, Pharmaceutical Institutions and Pharmaceuticals Law (2005) stipulated 
that any drug product must be priced before marketing and the price should be written 
on the product package in a clear way. Currently, the Saudi Food and Drug Authority 
(SFDA) is the national regulatory body responsible for registering, approving and 
pricing medicines. In fact, pricing is one of the essential steps during the registration 
process (SFDA, 2009).  The pricing of generic medicines is based on two guidelines, 
namely the common pricing criteria and the pricing rules of generic medicines (Hajed, 
2008). The common pricing criteria include considering the following factors when 
pricing any medicine (Hajed, 2008):  
• Ex-factory price in the country of origin (COO) 
• Wholesale price in the COO  
• Public (retail) prices in the COO and other countries where product is marketed  
• Cost, insurance and freight (CIF) price to Saudi Arabia in the COO currency  
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• CIF prices to countries in which the product is marketed (currently there are 30 
reference countries, namely Algeria, Argentina,  Australia, Bahrain, Belgium, 
Canada, Cyprus, Denmark, Egypt, France, Germany, Greece, Holland, Hungary, 
Ireland, Italy, Japan, Jordan, Kuwait, Lebanon, New Zealand, Oman, Portugal, 
South Korea, Spain, Sweden, Switzerland, Turkey, UAE and UK) 
• The price in official pricing references (if available) 
• Therapeutic significance of the product 
 
Based on the common pricing criteria, the lowest price should be selected and in all 
cases the pricing rules for generic medicines should be considered.  The SFDA pricing 
rules for generic medicines stated that the price of the first generic medicine to be 
marketed should be at least 30% lower than the price of the original brand medicine. 
After that, the price of the second generic medicine to be marketed should be at least 
10% lower than the first generic medicine registered on the market. Then, when 
registering any generic medicine (3rd or 4th etc), it should be 10% lower than the price 
of the last generic medicine registered on the market.   
 
Thus, based on the common pricing criteria and pricing rule of generic medicines, the 
lowest price should be selected and fixed as the price of the generic medicine. This 
pricing system has led to significant differences in price between original brand 
medicines and generic medicines. Moreover, there is a significant difference in price 
among generic medicines for the same original brand medicine as shown by the study 
conducted by Alnutafy (2009). Table 2.1 and Table 2.2 illustrate the prices of 
simvastatin and ciprofloxacin as examples.   
23 
 
Table 2.1 The cost of simvastatin 40 mg (30s)* 
  Trade name        Price (SAR)     Price difference of 
brand to generic (SAR) 
Price difference of generic 
to brand  (% ) 
Zocor                          215.45 − − 
Simvaten                     89.40 126.05 140.99 
Simvast                       80.45 135.05 167.87 
Vasta                           72.40 143.05 197.58 
Simva                          65.15 150.3 230.70 
Simvagen                    59.80                               155.65 260.28 
*Data source: Saudi National Formulary (SNF) (2010) 
 
Table 2.2 The cost of ciprofloxacin 500 mg (10s)* 
 Trade name        Price (SAR)   Price difference of        
 brand to generic (SAR) 
Price difference of generic 
to brand  (% ) 
Ciprobay                101.35 − − 
Cipromax                62.05 39.30 63.34 
Ciproxen                 50.25 51.10 101.69 
Omacip                   33.05 68.30 206.56 
Ciproflacin              21.05 80.30 381.47 
Ciprolet                    9.70                               91.65 944.85 
*Data source: Saudi National Formulary (SNF) (2010) 
 
2.1.7 Access to health-care and medicines  
In the public health-care sector, health-care services and medicines are provided free of 
charge to all citizens and also to expatriates working in the government sector (Walston 
et al., 2008; Almaliky et al., 2011; Bawazir et al., 2013). However, due to several 
reasons (e.g. quality of care, long waiting times), it is common for those who are 
entitled to  free health-care to seek treatment and medical care at private hospitals and 
polyclinics. In 2011, it was estimated that 61.6% (n=26,327,464) of those who received 
care in the private sector were Saudi patients despite the fact that they were entitled to 
free care in the public sector (SMOH, 2011).   
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As expatriates working in the private sector are not entitled to free health-care in the 
public sector, in order to provide them with basic health-care cover, the Cooperative 
Health Insurance Act was passed in 1999. The aim of this insurance is to provide health 
cover for expatriates and their families or dependents who are working in the private 
sector in the kingdom. In this insurance scheme, it is compulsory for all employers to 
purchase health insurance for their employees and their families in the kingdom 
(Cooperative Health Insurance Act, 1999). The insurance covers all medical 
examinations and consultations, medical treatments, medicines, vaccines, child and 
maternity care, laboratory investigations, X-rays and hospital admissions and 
hospitalizations, including those related to pregnancy and delivery and surgical 
operations. However, some conditions are excluded from the cover. General health 
examinations, treatment for sexually transmitted diseases (STDs), HIV and AIDS 
medicines, treatment for hair loss, contraceptives, treatment for infertility, impotence, 
acne and any treatment related to obesity are not covered as stated in the executive 
regulation of this insurance (Cooperative Health Insurance Policy, 2009).  
 
Regarding access to medicines, according to the Health Professions Act 2005, 
medicines can be kept and sold only in pharmacies. Moreover, by law, the pharmacist is 
the only health-care professional who is authorized to dispense medicines. It is also 
prohibited for other health-care professionals to dispense or keep medicines in their 
clinics or offices except for emergency medicines (Health Professions Act 2005). 
Therefore, in the public sector, each hospital has a pharmacy services department. A 
pharmacy department usually has an inpatient pharmacy, outpatient pharmacy and 
emergency pharmacy. For primary health-care (PHC) centres, there is one pharmacy in 
